Project Grant HT94252310260
Award Date
10/1/23
Completion Date
9/30/27
Dollars Obligated
$921K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Miami, FL 33136, USA
Similar Awards
The University of Miami was awarded a $1,534,998 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, which runs from August 15, 2023 to August 14, 2026, will fund research on the role of diffuse large B-cell lymphoma genome complexity in shaping immune responses to anti-CD19 chimeric antigen receptor T-cell therapies. As a non-profit educational institution and experienced federal grant recipient, the University of...
The University of Miami has been awarded a $1,700,000.00 Project Grant from the Department of Defense (DoD) through the Military Medical Research and Development (CFDA 12.420) federal grant program. This grant will support advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The research funded under this 2-year grant, with a performance period from September 15, 2024 to September 14, 2026, will explore innovative...
The University of Miami received a $921,000 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The three-year award beginning September 15, 2021 will support single-cell analysis of LAG3 checkpoint inhibition in metastatic uveal melanoma. Through this research, the University aims to transform health care for service members and the public by investigating medical solutions for the...
This $1,347,118 Project Grant was awarded on May 15, 2023 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The funding supports research conducted by the University of Miami to target KIF20A, a kinesin with a novel, non-canonical role in castration-resistant prostate cancer. The research aims to transform health care for Service Members and the American public through innovative and impactful biomedical research investigating medical...
The University of Miami received a $1,534,759 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on the "RESTORATION OF INNER EAR CELLS IN THE HEARING LOSS-ASSOCIATED HUMAN INNER EAR SYSTEM". This 3-year award, with a period of performance from September 30, 2023 to September 29, 2026, will support the university's biomedical research efforts focused on developing new treatments and...
The University of Miami was awarded a $1,272,102 Project Grant from the Defense Health Agency through the Military Medical Research and Development program (CFDA 12.420) to develop proprietary arginine vasopressin receptor type 1A (AVPR1A) antagonists for treatment of lethal prostate cancer. The three-year award beginning May 1, 2023 will support research to investigate medical solutions for battlefield conditions through the support of basic, applied, and advanced biomedical research aimed at...
The University of Miami was awarded a $1,036,125 Project Grant from the Defense Health Agency to conduct research titled "TARGETING IMMUNOSUPPRESSIVE ADENOSINE TO ENHANCE VACCINIA VIRUS RENAL CANCER ONCOLYSIS". This 3-year award, running from September 1, 2023 to August 31, 2026, is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform healthcare for service members and the public. The research seeks to...
This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $894,330.00 to the University of Miami to conduct research targeting axonal regeneration pathways as a therapeutic approach to amyotrophic lateral sclerosis (ALS). The research project aims to transform healthcare for military service members, veterans, and the broader public by investigating innovative medical solutions. The award period runs from February...
This federal Project Grant award of $1,535,000.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), is funding research at the University of Miami's School of Medicine targeting the reflux-activated oncogenic mRNA translation program in esophageal adenocarcinoma. The 3-year award, which began on July 1, 2025, aims to transform healthcare for military service members, veterans, and the broader public through innovative and...
The University of Miami received a $153,500 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research on "ENGINEERING TARGETED EXOSOME-BASED THERAPEUTICS FOR REPROGRAMMING OF CANCER-ASSOCIATED FIBROBLASTS IN TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER". The 2-year award period runs from February 15, 2024 to February 14, 2026. The Project Grant supports the university's work to develop novel...